REBLOZYL Drug Profile

Summary for Tradename: REBLOZYL

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for REBLOZYL

Recent Clinical Trials for REBLOZYL

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
EuroBloodNet Association	PHASE2
Bristol-Myers Squibb	Phase 3
Bristol-Myers Squibb	Phase 2

See all REBLOZYL clinical trials

Pharmacology for REBLOZYL

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythroid Maturation Agent

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REBLOZYL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REBLOZYL Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for REBLOZYL Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for REBLOZYL

Last updated: April 13, 2026

Summary: REBLOZYL (luspotransumab), developed by Celgene/Bristol-Myers Squibb, markets as a treatment for anemia associated with myelodysplastic syndromes (MDS) and beta-thalassemia. It debuted in 2020, demonstrating significant sales growth driven by expanding indications and global approval; however, competition and regulatory factors influence its future trajectory.

Market Overview

Primary Indications:

• Anemia in adults with lower-risk myelodysplastic syndromes (MDS) with ring sideroblasts.
• Anemia in adults with beta-thalassemia requiring regular transfusions.

Approval Timeline:

• FDA approval (August 2020): for MDS.
• EMA approval (September 2020): for both MDS and beta-thalassemia.
• Additional approvals in Japan (March 2021).

Market Size and Penetration:

• Global MDS market estimated at USD 1.2 billion (2022).
• Beta-thalassemia market estimated at USD 850 million (2022).
• REBLOZYL's initial targeted market was limited by indications but expanded as approvals extended.

Competitive Landscape

Key Competitors:

• Azacitidine (Up to 50% of eligible patients receive this hypomethylating agent).
• Roxadustat (HIF-PH inhibitor for anemia in chronic kidney disease).
• Emerging gene editors and alternative therapies targeting anemia.

Positioning:

• REBLOZYL differentiates via its mechanism as a gamma-globin inducer, with a tailored approach for specific subpopulations.
• During 2021-2022, market share gained as physicians adopted the drug following EMA and FDA approvals.

Financial Trajectory

Year	Revenue (USD million)	Growth Rate	Key Drivers
2020	165	N/A	Limited initial sales, early adoption
2021	420	154%	Expanded indication, increased prescriptions
2022	845	101%	Broader access, adoption in Europe and Japan

Factors Impacting Revenue:

• Expanded indications.
• Increasing patient access.
• Pricing policies and reimbursement.
• Competition from other agents and biosimilars.

Upcoming Drivers:

• Approval for additional indications.
• Larger patient population adoption.
• Commercial expansion in Asia-Pacific.

Challenges and Risks

• Competitive landscape with generic and biosimilar pressure.
• Regulatory hurdles in new markets.
• Pricing restrictions in cost-sensitive regions.
• Potential safety signals impacting prescribing patterns.

Future Outlook

Projections indicate revenues could stabilize around USD 1.2 billion annually by 2025 if market expansion proceeds without major hurdles. Market growth momentum depends on approval timelines, clinical adoption rate, and competitive innovations.

Key Takeaways

• REBLOZYL has achieved rapid growth post-launch but faces ongoing competition.
• Its financial trajectory relies on expanding indications, geographic market penetration, and reimbursement policies.
• Market growth could plateau without new indications or improvements in safety and efficacy profiles.

FAQs

1. What are the primary markets for REBLOZYL? The primary markets are North America, Europe, and Japan, targeting patients with lower-risk MDS with ring sideroblasts and beta-thalassemia.

2. How does REBLOZYL compare to competitors? It offers a unique mechanism of action as a gamma-globin inducer. Its sales depend on physician acceptance over traditional therapies like azacitidine.

3. What factors are likely to influence its future sales? Regulatory approvals for additional indications, competitive pressures, reimbursement policies, and clinical trial results.

4. Are there any known safety concerns? In clinical trials, common adverse events include thrombosis and fatigue; safety profiles are generally stable but monitored continuously.

5. What is the outlook for international expansion? Global regulations and reimbursement policies will shape expansion; recent approvals in Asia-Pacific regions support growth potential.

---

References

[1] Bristol-Myers Squibb. (2022). REBLOZYL (luspotransumab) prescribing information.

[2] MarketWatch. (2022). "Global Myelodysplastic Syndromes Market Analysis."

[3] EvaluatePharma. (2023). "Biologic treatments in anemia management."

[4] European Medicines Agency. (2020). REBLOZYL approval documentation.

[5] U.S. Food and Drug Administration. (2020). REBLOZYL approval letter.